Scandinavian ChemoTech AB

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0009242654
SEK
3.78
1.88 (99.47%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Risky -

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 246.79%, its profits have risen by 37.1%
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 78 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.15

stock-summary
Return on Equity

-252.86%

stock-summary
Price to Book

24.45

Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Dec 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
256.6%
0%
256.6%
6 Months
142.31%
0%
142.31%
1 Year
89.0%
0%
89.0%
2 Years
-15.03%
0%
-15.03%
3 Years
-65.37%
0%
-65.37%
4 Years
-85.04%
0%
-85.04%
5 Years
-62.53%
0%
-62.53%

Scandinavian ChemoTech AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
67.44%
EBIT Growth (5y)
7.37%
EBIT to Interest (avg)
-13.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
1.65
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
50.88
EV to EBIT
-11.97
EV to EBITDA
-15.35
EV to Capital Employed
66.27
EV to Sales
11.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-553.46%
ROE (Latest)
-486.78%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -21.21% vs -13.16% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -92.31% vs -44.44% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.60",
          "val2": "3.30",
          "chgp": "-21.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.60",
          "val2": "-0.60",
          "chgp": "-166.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.50",
          "val2": "-1.30",
          "chgp": "-92.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-799.80%",
          "val2": "-318.90%",
          "chgp": "-48.09%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 86.36% vs 135.71% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 40.88% vs 35.07% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12.30",
          "val2": "6.60",
          "chgp": "86.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.30",
          "val2": "-12.50",
          "chgp": "65.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.60",
          "val2": "1.20",
          "chgp": "33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.10",
          "val2": "-13.70",
          "chgp": "40.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-513.00%",
          "val2": "-1,932.80%",
          "chgp": "141.98%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
2.60
3.30
-21.21%
Operating Profit (PBDIT) excl Other Income
-1.60
-0.60
-166.67%
Interest
0.40
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.50
-1.30
-92.31%
Operating Profit Margin (Excl OI)
-799.80%
-318.90%
-48.09%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -21.21% vs -13.16% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -92.31% vs -44.44% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
12.30
6.60
86.36%
Operating Profit (PBDIT) excl Other Income
-4.30
-12.50
65.60%
Interest
1.60
1.20
33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.10
-13.70
40.88%
Operating Profit Margin (Excl OI)
-513.00%
-1,932.80%
141.98%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 86.36% vs 135.71% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 40.88% vs 35.07% in Dec 2024

stock-summaryCompany CV
About Scandinavian ChemoTech AB stock-summary
stock-summary
Scandinavian ChemoTech AB
Pharmaceuticals & Biotechnology
Scandinavian ChemoTech AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused on cancer treatment and manufactures specialized medical equipment. The Company's product IQWave is an electrochemotherapy (ECT) device. The IQWave system enhances the effects of the chemotherapeutic substance by opening up small pores in the tumor cells, giving the injected chemotherapeutic substance (no more than 15 IU of bleomycin) direct access to the DNA of the target cells. Among the product's applications are hypernephroma, kaposi sarcoma, transitional cell carcinoma, head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma. The treatment can be used for cutaneous as well as subcutaneous tumors.
Company Coordinates stock-summary
Company Details
Medicon Village, Scheelevagen 2 , LUND None : 223 63
Registrar Details